Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Profound Medical (PROF : NSDQ)
 
 • Company Description   
Profound Medical Corp. is a medical technology company. It is focused on a therapeutics platform which provides the precision of real-time Magnetic Resonance Imaging technology for the incision-free ablation of diseased tissue. The company principally commercialized the TULSA-PRO(R) and Sonalleve(R) platforms. Profound Medical Corp. is based in Mississauga, Canada.

Number of Employees: 142

 
 • Price / Volume Information   
Yesterday's Closing Price: $4.04 Daily Weekly Monthly
20 Day Moving Average: 178,170 shares
Shares Outstanding: 30.12 (millions)
Market Capitalization: $121.69 (millions)
Beta: 0.55
52 Week High: $9.17
52 Week Low: $3.76
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -27.08% -28.36%
12 Week -40.06% -45.55%
Year To Date -46.20% -52.92%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
2400 SKYMARK AVENUE UNIT 6
-
MISSISSAUGA,A6 L4W 5K5
CAN
ph: 64-7476-1350
fax: 64-7847-3739
skilmer@profoundmedical.com http://www.profoundmedical.com
 
 • General Corporate Information   
Officers
Arun Menawats - Chief Executive Officer and Director
Rashed Dewan - Chief Financial Officer
Brian Ellacott - Director
Cynthia Lavoie - Director
Murielle Lortie - Director

Peer Information
Profound Medical (GSAC)
Profound Medical (CASI)
Profound Medical (ALCD.)
Profound Medical (OMNN)
Profound Medical (CGPI.)
Profound Medical (CATX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 74319B502
SIC: 3841
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 06/01/25
Next Expected EPS Date: 11/06/25
Share - Related Items
Shares Outstanding: 30.12
Most Recent Split Date: (:1)
Beta: 0.55
Market Capitalization: $121.69 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.43 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.56 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 11/06/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 3.09
Price/Cash Flow: -
Price / Sales: 10.28
EPS Growth
vs. Year Ago Period: -85.71%
vs. Previous Quarter: -44.44%
Sales Growth
vs. Year Ago Period: -0.99%
vs. Previous Quarter: -15.64%
ROE
06/30/25 - -89.74
03/31/25 - -70.41
12/31/24 - -62.13
ROA
06/30/25 - -73.06
03/31/25 - -57.22
12/31/24 - -49.90
Current Ratio
06/30/25 - 8.53
03/31/25 - 11.31
12/31/24 - 10.52
Quick Ratio
06/30/25 - 7.07
03/31/25 - 10.03
12/31/24 - 9.64
Operating Margin
06/30/25 - -343.97
03/31/25 - -269.35
12/31/24 - -245.95
Net Margin
06/30/25 - -343.97
03/31/25 - -269.35
12/31/24 - -245.95
Pre-Tax Margin
06/30/25 - -343.61
03/31/25 - -269.38
12/31/24 - -260.47
Book Value
06/30/25 - 1.31
03/31/25 - 1.69
12/31/24 - 2.01
Inventory Turnover
06/30/25 - 0.53
03/31/25 - 0.60
12/31/24 - 0.56
Debt-to-Equity
06/30/25 - 0.11
03/31/25 - 0.09
12/31/24 - 0.05
Debt-to-Capital
06/30/25 - 10.21
03/31/25 - 8.12
12/31/24 - 4.62
 

Powered by Zacks Investment Research ©